Danielle Ternyila | Authors

January 17, 2021

Data presented at the 2021 Gastrointestinal Cancers Symposium shows promise for the combination of camrelizumab plus apatinib for previously treated patients with esophageal squamous cell carcinoma.

December 10, 2020

An analysis of tamoxifen versus anastrozole showed no significant difference in terms of disease recurrence in postmenopausal women with locally excised ductal carcinoma in situ; however, the findings may highlight the understanding of associated toxicities.

December 05, 2020

Study results showed that adding navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.

December 04, 2020

Enzalutamide improved progression-free survival and increased time to prostate-specific antigen progression, compared with bicalutamide, in patients with nonmetastatic castration-resistant prostate cancer.